Informations:
Erreur:
ID
33355
Description
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01206881
Lien
https://clinicaltrials.gov/show/NCT01206881
Mots-clés
Versions (1)
- 06/12/2018 06/12/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
6 décembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Breast Cancer NCT01206881
Eligibility Breast Cancer NCT01206881
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01206881
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Breast Carcinoma
Item
pathologically proven breast cancer
boolean
C0678222 (UMLS CUI [1])
Locally advanced breast cancer inflammatory | Tumor Size
Item
inflammatory, locally advanced breast cancer or a tumor > 5 cm
boolean
C3495949 (UMLS CUI [1,1])
C0333348 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C0333348 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status < 2
boolean
C1520224 (UMLS CUI [1])
Left ventricular ejection fraction MUGA | Patients HER2 Positive
Item
lvef > 50% measured by muga (her2 positive patients)
boolean
C0428772 (UMLS CUI [1,1])
C0521317 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0521317 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
Bone Marrow function | Liver function | Renal function
Item
adequate bone marrow, liver and renal function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Informed Consent
Item
written informed consent must be obtained
boolean
C0021430 (UMLS CUI [1])
Cancer Other
Item
another malignancy within 5 years prior to study entry
boolean
C1707251 (UMLS CUI [1])
Investigational New Drugs
Item
concurrent treatment with an investigational agent
boolean
C0013230 (UMLS CUI [1])
Disease Study Subject Participation Status Contraindicated | Condition Study Subject Participation Status Contraindicated
Item
other disease or condition that contraindicates participation in the study
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444657 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444657 (UMLS CUI [2,3])
C2348568 (UMLS CUI [1,2])
C1444657 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444657 (UMLS CUI [2,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])